Lantheus Holdings Inc (LNTH)vsTeva Pharma Industries Ltd ADR (TEVA)
LNTH
Lantheus Holdings Inc
$100.98
-1.79%
HEALTHCARE · Cap: $6.80B
TEVA
Teva Pharma Industries Ltd ADR
$34.43
-2.71%
HEALTHCARE · Cap: $40.32B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 1022% more annual revenue ($17.35B vs $1.55B). LNTH leads profitability with a 18.0% profit margin vs 9.0%. LNTH appears more attractively valued with a PEG of 0.61. LNTH earns a higher WallStSmart Score of 67/100 (B-).
LNTH
Strong Buy67
out of 100
Grade: B-
TEVA
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-2.1%
Fair Value
$65.91
Current Price
$100.98
$35.07 premium
Intrinsic value data unavailable for TEVA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 76.5% YoY
Conservative balance sheet, low leverage
Every $100 of equity generates 23 in profit
Growing faster than its price suggests
Strong operational efficiency at 21.6%
Earnings expanding 72.2% YoY
Growing faster than its price suggests
Areas to Watch
1.2% revenue growth
Weak financial health signals
Moderate valuation
2.3% revenue growth
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : LNTH
The strongest argument for LNTH centers on EPS Growth, Debt/Equity, Return on Equity. Profitability is solid with margins at 18.0% and operating margin at 21.6%. PEG of 0.61 suggests the stock is reasonably priced for its growth.
Bull Case : TEVA
The strongest argument for TEVA centers on EPS Growth, PEG Ratio. PEG of 0.85 suggests the stock is reasonably priced for its growth.
Bear Case : LNTH
The primary concerns for LNTH are Revenue Growth, Piotroski F-Score.
Bear Case : TEVA
The primary concerns for TEVA are P/E Ratio, Revenue Growth, Free Cash Flow. Debt-to-equity of 2.05 is elevated, increasing financial risk.
Key Dynamics to Monitor
TEVA carries more volatility with a beta of 0.85 — expect wider price swings.
TEVA is growing revenue faster at 2.3% — sustainability is the question.
LNTH generates stronger free cash flow (122M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LNTH scores higher overall (67/100 vs 66/100), backed by strong 18.0% margins. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Lantheus Holdings Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Lantheus Holdings, Inc. develops, manufactures and markets diagnostic and therapeutic agents and products that assist physicians in the diagnosis and treatment of heart, cancer and other diseases worldwide. The company is headquartered in North Billerica, Massachusetts.
Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?